60 Wentworth Road
Rye, NH 03870
NH High Tech Council Bio/Medical Forum to Focus on “Solving The Payer Problem” with Keynote David Balekdjian
The NH High Tech Council will welcome David Balekdjian, CEO of the Bruckner Group, at its next Bio/Medical Forum on September 11 at the Wentworth Country Club in Rye, NH beginning at 6 pm.
Balekdjian will be discussing the “payer problem” and why most biomedical companies fall short, while those who get it right obtain larger partnering deals, increase investor ROI, and generate larger revenue streams. The Bruckner Group is a biopharmaceutical strategy consultancy founded in Boston in 2001 and are the pioneers and industry leaders in healthcare value strategy, as well as payer strategy experts and thought-leaders.
“We’re excited to pull together members of the bio/medical and community-at-large in an informal setting and have David Balekdjian share his deep expertise with us,” said Catherine Blake, Co-Chair of the Forum and member of the Council’s Board of Directors. “David brings a unique perspective on developing optimal clinical pathways for new product commercialization while laying a solid foundation for reimbursement.”
The Bio/Medical Forum is a community of industry professionals enthusiastic to grow instances of biotechnology, life sciences, medical devices and diagnostics in New Hampshire. The High Tech Council established the Forum in 2013 as a way for individuals within this sector to connect in a fun and informative ways.
Balekdjian was the first in the biopharmaceutical industry to publish on the payer paradigm shift and its implications for the pharma/biotech business model. He and the Bruckner team have remained at the forefront of helping companies successfully achieve their goals in a payer-centric marketplace. They have developed a proprietary, proven approach to value proposition development that consistently produces results others are not achieving. Balekdjian has authored or co-authored nearly two dozen papers and articles internationally. Most recently in November 2013, he published “Surpassing Expectations: Increasing Deal Value Through Better Drug Value Propositions” in In Vivo. David co-authored the highly influential paper “Weighing The Outcomes” in Nature Biotechnology—which has become the standard reference paper on how to optimize new therapeutic value propositions to payers. Balekdjian has been featured in a number of publications, including Business Week.